Completed
PHASE3
INTERVENTIONAL
NCT04657003
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This is a study of tirzepatide in participants with type 2 diabetes who have obesity or are overweight. The main purpose is to learn more about how tirzepatide affects body weight. The study will last 79 weeks (22 visits).
Interventions
Name:
Tirzepatide
Type:
DRUG
Description:
Administered SC
Name:
Placebo
Type:
OTHER
Description:
Administered SC
Primary Outcomes
Measure:
Percent Change From Baseline in Body Weight
TimeFrame:
Baseline, Week 72
Description:
Least Squares Mean (LSMean) calculated using Mixed Model Repeated Measures (MMRM) model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Type of Antihyperglycemic Medication (AHM) Used at Randomization + Treatment + Time + Treatment\*Time (Type III sum of squares).
Measure:
Percentage of Participants Who Achieve ≥5% Body Weight Reduction From Baseline
TimeFrame:
Week 72
Description:
Percentage of participants who achieve ≥5% body weight reduction from baseline
Trial Information
NCT ID
NCT04657003
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025